ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 07/23/2014

ClinicalTrials.gov ID: NCT01010503

Study Identification

Unique Protocol ID:	ML22508
Brief Title:	A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
Official Title:	Evaluation of Adherence and Persistence to Tocilizumab in Combination With Methotrexate or Tocilizumab Monotherapy in Patients With Moderate to Severe Active Rheumatoid Arthritis in Local Environment.
Secondary IDs:	2009-011520-53

Study Status

Record Verification:	July 2014
Overall Status:	Completed
Study Start:	June 2009
Primary Completion:	May 2010 [Actual]
Study Completion:	May 2010 [Actual]

Sponsor/Collaborators

Sponsor:	Hoffmann-La Roche
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	No
IND/IDE Protocol?:	No

Review Board:	Approval Status: Approved Approval Number: 20 APRIL 2009 Board Name: Ethic Committee at the National Institute for Rheumatic Diseases Board Affiliation: National Institute for Rheumatic Diseases/ Národný ústav reumatických chorôb Phone: +421 33 7969111 Email: rovensky@nurch.sk
Data Monitoring?:	
Plan to Share Data?:	
Oversight Authorities:	Slovakia: State Institute for Drug Control

Study Description

Brief Summary:	This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to non-biologic DMARDs. Patients will receive tocilizumab 8 mg/kg as intravenous infusion once every 4 weeks in combination with methotrexate or in case of intolerance to methotrexate as monotherapy. The anticipated time of study treatment is 6 months. The target sample size is 20-50 patients.
Detailed Description:	

Conditions

Conditions:	Rheumatoid Arthritis
Keywords:	

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 4
Intervention Model:	Single Group Assignment
Number of Arms:	1
Masking:	Open Label
Allocation:	N/A
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	32 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: Single Arm	Drug: tocilizumab [RoActemra/Actemra] tocilizumab 8 mg/kg intravenous infusion once in 4 weeks

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 18 Years

Maximum Age:

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- adult patients >/= 18 years of age
- moderate to severe active rheumatoid arthritis
- inadequate response, or intolerance to previous therapy with one or more traditional DMARDs
- DAS >3.6
- pneumology examination (including chest x-ray and quantiferon)

Exclusion Criteria:

- < 18 years of age
- active infection
- active tuberculosis
- uncontrolled hyperlipoproteinaemia
- demyelinating disorders
- concomitant anti-TNF drugs
- history of intestinal ulceration and diverticulitis

Contacts/Locations

Study Officials: Clinical Trials
Study Director
Hoffmann-La Roche

Locations: Slovakia

Piestany, Slovakia, 921 12

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Reporting Groups

	Description
Tocilizumab 8 Milligrams Per Kilogram (mg/kg)	Participants received tocilizumab 8 mg/kg intravenously (IV) once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Overall Study

	Tocilizumab 8 Milligrams Per Kilogram (mg/kg)
Started	32
Completed	30
Not Completed	2
Adverse Event	1
Death	1

Baseline Characteristics

Analysis Population Description

All participants who received at least one dose of study drug.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Baseline Measures

	Tocilizumab 8 mg/kg
Number of Participants	32
Age, Continuous [units: years] Mean (Standard Deviation)	52.38 (12.05)
Gender, Male/Female [units: participants]	
Female	26
Male	6
Race (NIH/OMB) [units: participants]	
American Indian or Alaska Native	0
Asian	0
Native Hawaiian or Other Pacific Islander	0
Black or African American	0
White	32
More than one race	0
Unknown or Not Reported	0
Region of Enrollment Slovakia [units: participants]	32
Disease Duration [units: years] Mean (Standard Deviation)	11.97 (10.55)
Disease Phase/Stage [1] [units: participants]	
Phase/Stage I	4

	Tocilizumab 8 mg/kg
Phase/Stage II	12
Phase/Stage III	12
Phase/Stage IV	4
Functional Class of Disease [2] [units: participants]	
Class I	0
Class II	10
Class III	22
Class IV	0
C-Reactive Protein (CRP) [3] [units: mg/L] Mean (Standard Deviation)	17.84 (21.30)
Erythrocyte Sedimentation Rate (ESR) [4] [units: mm/hr] Mean (Standard Deviation)	55.81 (25.05)

[1] Disease stages/phases of rheumatoid arthritis (RA): Stage I represents synovitis: synovial membrane becomes hyperemic and edematous; joint effusions with high cell count; x-rays will as yet show no destructive changes, but soft tissue swelling or osteoporosis may be seen; Stage II: inflamed synovial tissue now proliferates and begins to grow into joint cavity across articular cartilage, which it gradually destroys; Stage III: pannus of synovium; eroded articular cartilage and exposed subchondral bone x-rays will show extensive cartilage loss; Stage IV represents end-stage disease.

[2] Classification of global functional status in RA is as follows: Class I: completely able to perform usual activities of daily living (self-care, vocational, and avocational); Class II: able to perform usual self-care and vocational activities, but limited in avocational activities; Class III: able to perform usual self-care activities, but limited in vocational and avocational activities; and Class IV: limited in ability to perform usual self-care, vocational, and avocational activities.

[3] CRP was measured in milligrams per liter (mg/L)

[4] ESR was measured in millimeters per hour (mm/hr)

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Percentage of Participants Adherent to Original Treatment

Measure Description	Adherence rate to original treatment according to the protocol included all participants that received the study drug beginning from Week 8 and remaining until the end of the study. This number represents participants with no changes in treatment protocol, participants with treatment discontinuation, and participants with dose reduction, but not participants that withdrew from the study prematurely.
Time Frame	Week 24
Safety Issue?	No

Analysis Population Description

Intent-to-treat population (ITT), all enrolled participants who received at least one dose of study drug

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Percentage of Participants Adherent to Original Treatment [units: percentage of participants]	93.75

2. Primary Outcome Measure:

Measure Title	Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason
Measure Description	
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT Population

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason [units: percentage of participants]	3.13

3. Primary Outcome Measure:

Measure Title	Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason
Measure Description	
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT Population

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Percentage of Participants Receiving Greater Than (>) 1 Dose Who Discontinued Treatment for Any Reason [units: percentage of participants]	0

4. Primary Outcome Measure:

Measure Title	Percentage of Participants Withdrawing From the Study Prematurely for Any Reason
Measure Description	
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT Population

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Percentage of Participants Withdrawing From the Study Prematurely for Any Reason [units: percentage of participants]	6.25

5. Primary Outcome Measure:

Measure Title	Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg
Measure Description	
Time Frame	Weeks 0, 4, 8, 12, 16, and 20
Safety Issue?	No

Analysis Population Description

ITT Population

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Percentage of Participants With Dose Reduction to Tocilizumab 4 mg/kg [units: percentage of participants]	18.75

6. Secondary Outcome Measure:

Measure Title	Disease Activity Score Based on 28-Joint Count (DAS28)
Measure Description	DAS28 calculated from the number of swollen joints and tender joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity.
Time Frame	Weeks 0, 4, 12, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Disease Activity Score Based on 28-Joint Count (DAS28)	

	Tocilizumab 8 mg/kg
[units: units on a scale] Mean (Standard Deviation)	
Week 0 (n=32)	7.02 (0.66)
Week 4 (n=32)	4.30 (1.04)
Week 12 (n=30)	2.85 (1.11)
Week 24 (n=30)	2.57 (0.91)

7. Secondary Outcome Measure:

Measure Title	Patient Global Assessment of Pain
Measure Description	Participants were asked to rate their pain using a 0 to 100 mm visual analog scale (VAS), where 0 mm = no pain and 100 mm = worst possible pain. The participant was asked to mark the line corresponding to their perceived level of pain and the distance in mm from the left edge of the scale was measured.
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Patient Global Assessment of Pain [units: units on a scale] Mean (Standard Deviation)	
Week 0 (n=32)	59.91 (14.66)
Week 4 (n=32)	36.31 (17.10)
Week 8 (n=30)	22.3 (15.79)

	Tocilizumab 8 mg/kg
Week 12 (n=30)	17.30 (14.00)
Week 16 (n=30)	18.93 (14.59)
Week 20 (n=30)	16.73 (15.11)
Week 24 (n=30)	14.87 (11.32)

8. Secondary Outcome Measure:

Measure Title	Patient Global Assessment of Disease Activity
Measure Description	The participant's assessment of disease activity was performed using a 100 mm VAS ranging from no activity (0) to maximal activity (100). The participant was asked to mark the line corresponding to their perceived level of disease activity and the distance in mm from the left edge of the scale was measured.
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Patient Global Assessment of Disease Activity [units: units on a scale] Mean (Standard Deviation)	
Week 0 (n=32)	61.75 (11.76)
Week 4 (n=32)	35.59 (16.62)
Week 8 (n=30)	22.20 (14.86)
Week 12 (n=30)	18.20 (14.57)

	Tocilizumab 8 mg/kg
Week 16 (n=30)	18.80 (13.42)
Week 20 (n=30)	18.13 (18.49)
Week 24 (n=30)	15.47 (12.62)

9. Secondary Outcome Measure:

Measure Title	Physician's Global Assessment of Disease Activity
Measure Description	Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The physician was asked to mark the line corresponding to their perceived level of the participant's disease activity and the distance in mm from the left edge of the scale was measured.
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Physician's Global Assessment of Disease Activity [units: units on a scale] Mean (Standard Deviation)	
Week 0 (n=32)	59.63 (7.89)
Week 4 (n=32)	27.75 (14.00)
Week 8 (n=30)	17.40 (9.96)
Week 12 (n=30)	14.20 (9.93)
Week 16 (n=30)	13.00 (8.68)

	Tocilizumab 8 mg/kg
Week 20 (n=30)	12.77 (10.17)
Week 24 (n=30)	12.47 (8.22)

10. Secondary Outcome Measure:

Measure Title	Swollen Joint Count (SJC)
Measure Description	The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not swollen or 1=swollen. The total number was calculated from all the joints for a maximum score of 28.
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Swollen Joint Count (SJC) [units: swollen joints] Mean (Standard Deviation)	
Week 0 (n=32)	26.66 (7.11)
Week 4 (n=32)	12.03 (8.24)
Week 8 (n=30)	7.00 (6.52)
Week 12 (n=30)	5.33 (6.47)
Week 16 (n=30)	5.33 (6.33)

	Tocilizumab 8 mg/kg
Week 20 (n=30)	4.20 (5.088)
Week 24 (n=30)	4.00 (5.24)

11. Secondary Outcome Measure:

Measure Title	Tender Joint Count (TJC)
Measure Description	The following 28 joints were assessed by the physician for tenderness: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). Joints were rated as 0=not tender or 1=tender. The total number was calculated from all the joints for a maximum score of 28.
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Tender Joint Count (TJC) [units: tender joints] Mean (Standard Deviation)	
Week 0 (n=32)	16.16 (5.18)
Week 4 (n=32)	5.53 (5.16)
Week 8 (n=30)	1.97 (2.01)
Week 12 (n=30)	1.30 (1.68)
Week 16 (n=30)	1.00 (1.20)
Week 20 (n=30)	0.83 (1.315)

	Tocilizumab 8 mg/kg
Week 24 (n=30)	0.63 (1.00)

12. Secondary Outcome Measure:

Measure Title	Erythrocyte Sedimentation Rate (ESR)
Measure Description	ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation.
Time Frame	Weeks 0, 4, 12, 20, and 24
Safety Issue?	No

Analysis Population Description

TT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Erythrocyte Sedimentation Rate (ESR) [units: mm/hr] Mean (Standard Deviation)	
Week 0 (n=32)	55.81 (25.05)
Week 4 (n=32)	16.69 (10.88)
Week 12 (n=30)	15.23 (14.78)
Week 20 (n=30)	14.17 (17.81)
Week 24 (n=30)	11.00 (7.94)

13. Secondary Outcome Measure:

Measure Title	C-Reactive Protein (CRP)
Measure Description	CRP is an acute phase protein. Levels of CRP increase with inflammation.
Time Frame	Weeks 0, 4, 12, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
C-Reactive Protein (CRP) [units: mg/L] Mean (Standard Deviation)	
Week 0 (n=32)	17.84 (21.30)
Week 4 (n=32)	5.03 (6.07)
Week 12 (n=30)	5.54 (9.22)
Week 20 (n=30)	6.71 (13.9)
Week 24 (n=30)	2.97 (0.70)

14. Secondary Outcome Measure:

Measure Title	Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

Measure Description	The HAQ-DI was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
Time Frame	Weeks 0, 4, 8, 12, 16, 20, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score [units: scores on a scale] Mean (Standard Deviation)	
Week 0 (n=32)	1.77 (0.43)
Week 4 (n=32)	1.56 (0.49)
Week 8 (n=30)	1.31 (0.65)
Week 12 (n=30)	1.28 (0.65)
Week 16 (n=30)	1.23 (0.64)
Week 20 (n=30)	1.20 (0.644)
Week 24 (n=30)	1.16 (0.63)

15. Secondary Outcome Measure:

Measure Title	Short Form-36 (SF-36)
Measure Description	The SF-36 measures the impact of disease on overall quality of life and consists of 8 subscales (physical function, pain, general and mental health, vitality, social function, physical and emotional health) which can be aggregated to derive a physical-component summary score and a mental-component summary score. Scores for each subscale range from 0 to 10, and the composite scores range from 0 to 100, with higher scores indicating better health.
Time Frame	Weeks 0, 12, and 24
Safety Issue?	No

Analysis Population Description

ITT population; n=number of participants assessed for the specified parameter at a given visit.

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Measured Values

	Tocilizumab 8 mg/kg
Number of Participants Analyzed	32
Short Form-36 (SF-36) [units: scores on a scale] Mean (Standard Deviation)	
Physical Functioning, Week 0 (n=32)	26.08 (18.09)
Physical Functioning, Week 12 (n=30)	44.50 (27.58)
Physical Functioning, Week 24 (n=30)	47.22 (31.92)
Role limits due to physical health, Week 0 (n=32)	6.25 (18.71)
Role limits due to physical health, Week 12 (n=30)	49.17 (45.34)
Role limits due to physical health, Week 24 (n=30)	44.44 (45.60)
Role limits due to emotional prob., Week 0 (n=32)	16.67 (34.23)
Role limits due to emotional prob., Week 12 (n=30)	61.11 (45.34)
Role limits due to emotional prob., Week 24 (n=30)	55.56 (48.47)
Energy/fatigue, Week 0 (n=32)	30.31 (17.93)
Energy/ fatigue, Week 12 (n=30)	48.33 (26.14)

	Tocilizumab 8 mg/kg
Energy/fatigue, Week 24 (n=30)	50.00 (31.32)
Emotional well-being, Week 0 (n=32)	50.00 (19.10)
Emotional well-being, Week 12 (n=30)	63.70 (24.16)
Emotional well-being, Week 24 (n=30)	65.33 (32.92)
Social functioning, Week 0 (n=32)	39.45 (17.61)
Social functioning, Week 12 (n=30)	60.83 (25.36)
Social functioning, Week 24 (n=30)	62.50 (35.11)
Pain, Week 0 (n=32)	28.67 (15.34)
Pain, Week 12 (n=30)	55.75 (27.63)
Pain, Week 24 (n=30)	56.11 (33.32)
General health, Week 0 (n=32)	38.28 (10.82)
General health, Week 12 (n=30)	46.83 (16.32)
General health, Week 24 (n=30)	46.25 (23.41)

Reported Adverse Events

Time Frame	Serious adverse events (SAEs) related to study medication were reported irrespective of elapsed time from last administration of study medication. Non-related SAEs were reported during the study period and 28 days after the last dose of study medication.
Additional Description	[Not specified]

Reporting Groups

	Description
Tocilizumab 8 mg/kg	Participants received tocilizumab 8 mg/kg IV once every 4 weeks for a maximum of 20 weeks (total of 6 infusions).

Serious Adverse Events

	Tocilizumab 8 mg/kg	
	Affected/At Risk (%)	# Events
Total	3/32 (9.38%)	
Cardiac disorders		
Congestive heart failure [A] *	1/32 (3.12%)	
Infections and infestations		
Bronchopneumonia [A] *	1/32 (3.12%)	
Crash of left foot local infection of skin and subcutaneous tissue [A] *	1/32 (3.12%)	
Musculoskeletal and connective tissue disorders		
Lumbago [A] *	1/32 (3.12%)	

* Indicates events were collected by non-systematic methods.
A Term from vocabulary, MedDRA (10.0)

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 0%

	Tocilizumab 8 mg/kg	
	Affected/At Risk (%)	# Events
Total	10/32 (31.25%)	
Blood and lymphatic system disorders		
Leucopenia+lymphopenia [A] †	3/32 (9.38%)	3
Hepatobiliary disorders		
Hepatopathy [A] †	2/32 (6.25%)	2
Infections and infestations		
Acute pulpitis [A] †	1/32 (3.12%)	2
Reproductive system and breast disorders		
Acute bronchitis [A] †	3/32 (9.38%)	3
Respiratory, thoracic and mediastinal disorders		

	Tocilizumab 8 mg/kg	
	Affected/At Risk (%)	# Events
Acute nasopharyngitis [A] †	1/32 (3.12%)	1

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA (10.0)

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The study being conducted under this agreement is part of the overall study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study, but after the first publication or presentation that involves the overall study. Sponsor may request that confidential information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights

Results Point of Contact:

Name/Official Title: Medical Communications
Organization: Hoffmann- LaRoche.
Phone: 800-821-8590
Email: genentech@druginfo.com